Top 50 Biotech VC (Venture Capital) Funds in Germany in May 2025

Investor	Biotech Germany investments
High-Tech Gruenderfonds	43
MIG Capital	16
KfW	16
Boehringer Ingelheim Venture Fund	16
NRW.BANK	15
Bayern Kapital	11
Wellington Partners	9
b.value AG	9
IFB Innovationsstarter	8
TGFS - Technologiegründerfonds Sachsen	8
BioMedPartners	7
Techno Venture Management	7
Forbion Capital Partners	6
coparion	6
eCAPITAL ENTREPRENEURIAL PARTNERS	6
Creathor Ventures	5
bmp Ventures	5
IBB Ventures	5
BayBG Venture Capital	5
EMBL Ventures	5
bm-t beteiligungsmanagement thuringen	5
LSP BioVentures	4
Seed Fonds Aachen	4
CPT Capital	4
EQT Ventures	4
Andera Partners	4
Brandenburg Kapital	4
BlueYard Capital	4
Amino Collective	4
S-Venture Capital Dortmund	4
Grazia Equity	4
German Federal Ministry of Education and Research	4
EIC Fund	4
SFO	3
DvH Ventures	3
UVC Partners	3
Gilde Healthcare	3
Good Seed Ventures	3
Possible Ventures	3
Agronomics	3
Seventure Partners	3
Global Asset Fund	3
Lowercarbon Capital	3
Delivery Hero Ventures	3
better ventures	3
Ananda Impact Ventures	3
EQT Life Sciences	3
TechVision Fund	3
TVM Capital	3
Cascara Ventures	3

The seed investor High-Tech Gründerfonds (HTGF) finances tech start-ups with growth potential and has supported more than 700 start-ups since 2005. With the launch of its fourth fund, HTGF now has about 1.4 billion euros under management. Its team of experienced investment managers and start-up experts support young companies with expertise,entrepreneurial spirit and passion. HTGF’s focus is on high-tech start-ups in the fields of digital tech, industrial tech, life sciences, chemistry and related business areas. To date, external investors have injected about 5 billion euros of capital into the HTGF portfolio via more than 2,000 follow-on financing rounds. In addition, HTGF has already successfully sold shares in more than 170 companies. Fund investors in this public-private partnership include the German Federal Ministry for Economic Affairs and Climate Action, KfW Capital and 45 companies from a wide range of industries. Fund investors in this public-private partnership include the German Federal Ministry for Economic Affairs and Climate Action, KfW Capital and 45 companies from a wide range of industries.

Investment focus

Software, Biotechnology, Information Technology
Seed, Series A, Funding Round
Germany, Switzerland, United States

Portfolio highlights

mo:re GmbH — Mo:re is building the new gold standard for organoid-based drug development by offering a lab platform that industrialises cell culture workflows.
Eyeo — eyeo revolutionizes imaging with color splitter sensors. Capture sharper, brighter images in low light using optical waveguide innovation, discover how it works
AICA SA — AICA believes programming robots should be at everyone's reach. We combine Artificial Intelligence & an intuitive interface, to help you relocate your production.

Zusammen gestalten wir die Unternehmen von morgen.

Investment focus

Biotechnology, Health Care, Medical
Series A, Funding Round, Series B
Germany, France, Austria

Portfolio highlights

Inbolt — InBolt has developed the world’s smallest and most efficient 3D camera tracking system. Their first product is a hardware module / device that an operator can plug onto all manual tools such as a drill, a screwdriver or a torque wrench. Once on the tool, it guides the operator, validates the completion of a task in real time and registers allthe completion parameters.
SciRhom — SciRhom GmbH is a biotech company that translates science into the preclinical and early clinical development of novel biopharmaceuticals for the treatment of life-threatening autoimmune diseases. Based on longstanding academic research and a well-established network of experts, SciRhom was founded in 2016 through a collaboration between academicand industry scientists with profound experience in antibody development.
Innatera — Innatera is a Dutch nanotech company and an offspring of the Delft University of Technology in the Netherlands.

KfW gives impetus to economic, social and ecological development worldwide. As a promotional bank under the ownership of the Federal Republic and the LÃ¤nder (federal states), it offers support to encourage sustainable improvement in economic, social, ecological living and business conditions, among others in the areas of small and medium-sizedenterprise, entrepreneurialship, environmental protection, housing, infrastructure, education finance, project and export finance, and development cooperation.

Investment focus

Biotechnology, Software, Health Care
Funding Round, Series A, Series B
Germany, India, Kenya

Portfolio highlights

Vectoflow — Vectoflow is an innovative company developing fluid-dynamic metrology devices for fluid flow and dynamics measurement. It offers standardized and customized flow measurement technology that measures the static and total pressure, velocity, and angle of attack of a flow. These products are used in motorsport, aviation, turbine machine development,and research sectors.
Electrochaea — Electrochaea is commercializing a disruptive, scalable technology to convert electric power into methane, the principal component of natural gas. Using CO2 as a feedstock gas, power can be efficiently converted to renewable natural gas for power storage, for transportation fuels, or for transmission via a natural gas network. The company licensedtechnology from the University of Chicago and is led by the Nidus Partners, a St. Louis investment group specializing in renewable energy. Mich Hein, a Nidus Managing Partner, serves as CEO.Electrochaea has developed a commercially viable and disruptive solution for utility-scale energy storage, grid balancing, and carbon reuse. Their proprietary process converts low-cost and stranded electricity and carbon dioxide into pipeline-grade renewable gas for direct injection into the existing natural gas grid, a conversion process known as “power-to-gas”.
CryoTherapeutics — USING CRYOTHERAPY TO TREAT AND PREVENT HEART ATTACKS

The Boehringer Ingelheim Venture Fund is the strategic venture fund of the Boehringer Ingelheim Corporation.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Seed
United States, Germany, Belgium

Portfolio highlights

Nuevocor — Nuevocor is a preclinical-stage biopharmaceutical company focused on developing gene therapy‑based treatments that have the potential to restore cardiac function in diseased hearts.
Brainomix — Since launching as a spin-out from the University of Oxford in 2010, Brainomix has developed award-winning, AI-powered imaging biomarkers, assisting physicians across the world to make better life-saving decisions. Brainomix seminal product, e-Stroke is a collection of tools that use state-of-the-art AI algorithms to support doctors by providingreal-time interpretation of brain scans to help guide treatment and transfer decisions for stroke patients, allowing more patients to get the right treatment, in the right place, at the right time.
Aignostics — Aignostics is an AI-powered precision diagnostics focused on pathology to assist with drug development and clinical research. Its “explainable” AI overcomes the “black-box” limitations of conventional AI. Based on their patented technology for reverse-engineering the black box, they render diagnostic results explainable in the form of preciseheatmaps and image overlays. These heatmaps allow pathologists to quickly verify the results of the AI, which is crucial, as the pathologist is ultimately responsible for the diagnosis.The company was founded in 2018 and is headquartered in Berlin, Germany.

NRW.BANK is the development bank for the state of North Rhine-Westphalia. It supports its owner – the state of North Rhine-Westphalia – in fulfilling its tasks, notably in the fields of structural, economic, social and housing policy. NRW.BANK pools the promotion and development programmes of the state of North Rhine-Westphalia, the FederalRepublic of Germany and the European Union and combines them with its own equity and debt products and advisory services. It offers the full range of financial products in three areas “Economy”, “Housing”, and “Infrastructure/Municipalities”. NRW.BANK operates in a competitively neutral manner as a partner of banks and savings banks.

Investment focus

Software, Biotechnology, Information Technology
Seed, Series A, Series B
Germany, United States, France

Portfolio highlights

Pilzling — Bio-Pilze direkt aus deiner Stadt.
ScrapBees — ScrapBees is a pick-up service for the recycling of scrap metal from commercial businesses and private households.
Alteva — Alteva develops battery cells for the decarbonisation of the global transport sector, and focus on high-energy density battery cells with high safety profiles specifically designed for the aviation and heavy-duty transport sectors.

Bayern Kapital (founded at the end of 1995) is a wholly owned subsidiary of the LfA Foerderbank Bayern (Bavaria‘s development bank). Bayern Kapital’s objective is to finance research and development as well as the market launch of new products, product diversifications, and expansion of the market share.The requesting company has to be located inBavaria. Industries are e. g. IT/software, life sciences, new materials, micro-systems and environmental technologies.Bayern Kapital and its funds have invested in more than 250 companies and currently manages funds to the value of EUR 340 m. The five investing funds currently managed by Bayern Kapital are Seedfonds Bayern, Clusterfonds Start-Up!, Innovationsfonds, Innovationsfonds EFRE and Wachstumsfonds Bayern.

Investment focus

Software, Health Care, Information Technology
Seed, Series A, Funding Round
Germany, United States, Finland

Portfolio highlights

AlfaDocs — Il primo software in cloud pensato per la gestione completa dello studio medico e dentistico e della relazione medico-paziente. Provalo subito gratis!
OroraTech — From safeguarding forests and ecosystems to protecting communities and critical assets, OroraTech's advanced technology and reliable insights address challenges, mitigate risks, and drive meaningful impact.
Ubimaster — Ubimaster provides personalised employee benefits and additional product services that support parents and students.

Wellington Partners is a venture capital firm that invests in technology and life sciences companies, focusing on Digital Media, Software, Electronics & Photonics, Resource Efficiency, and Biotech/Life Sciences. It is committed to providing outstanding entrepreneurs with the necessary resources to fund their strategies. We typically leadfinancing rounds ranging from € 0.5 million to € 20 million. Depending on the maturity of the company, its own commitment can go as high as € 15 million.Wellington was established in 1998 and has offices in Munich, London, and Zurich.

Investment focus

Health Care, Biotechnology, Medical
Series A, Series B, Funding Round
Germany, United States, United Kingdom

Portfolio highlights

Hilo — Get stress-free readings round the clock with Hilo's clinically validated blood pressure monitor. Learn more
Aignostics — Aignostics is an AI-powered precision diagnostics focused on pathology to assist with drug development and clinical research. Its “explainable” AI overcomes the “black-box” limitations of conventional AI. Based on their patented technology for reverse-engineering the black box, they render diagnostic results explainable in the form of preciseheatmaps and image overlays. These heatmaps allow pathologists to quickly verify the results of the AI, which is crucial, as the pathologist is ultimately responsible for the diagnosis.The company was founded in 2018 and is headquartered in Berlin, Germany.
HepaRegeniX — HepaRegeniX is developing drugs for treating acute and chronic liver diseases that effectively restore the regenerative capacity of hepatocytes. The therapeutic concept is founded on research by Professor Lars Zender’s group at the University Hospital Tübingen, which identified mitogen-activated protein (MAP) kinase kinase 4 (MKK4) as a keyregulator of liver regeneration. Work by Professor Zender’s team showed that using small RNA molecules to suppress MKK4 gene expression restored the regenerative capacity of hepatocytes, even in severely diseased livers. Founded in 2015, HepaRegeniX is developing small-molecule MKK4 inhibitors to treat liver disorders, potentially including nonalcoholic steatohepatitis.

b.value AG are into Biotechnology investments.

Investment focus

Biotechnology, Manufacturing, Chemical
Seed, Funding Round, Series A
Germany, Poland

Portfolio highlights

PL BioScience — Animal-free cell culture supplements derived from human platelets. Supporting cell expansion and maintenance from research to therapy.
Cultimate Foods — Cultimate Foods is a cellular agriculture company. It develops cultivated fat for hybrid alt-meat products. It's cultivated fat replicates the structure of animal fat tissue and it uses a "unique technological approach to 3D cultivation that creates the structure of their ingredient and reduces production costs."
traceless materials — traceless materials offer a holistically sustainable alternative to plastics: 100% biobased on plant residues, compostable under natural conditions, and free of toxic chemicals. For a future free of pollution and waste!

The IFB Innovationsstarter is an innovation funding and investment company of the City of Hamburg providing grants and investments.

Investment focus

Software, SaaS, Artificial Intelligence
Seed, Funding Round, Grant
Germany, United States

Portfolio highlights

mo:re GmbH — Mo:re is building the new gold standard for organoid-based drug development by offering a lab platform that industrialises cell culture workflows.
Tomorrow — Tomorrow combines mobile banking with sustainability. Open your sustainable account in minutes & start protecting the climate right away.
Neuralfinity — Build Generative AI Models That Truly Deliver: Create datasets, train from scratch, and evaluate generative AI models like LLMs and VLMs.

TGFS - Technologiegruenderfonds Sachsen is an early stage VC fund targeting high tech startups with strong growth potential. The fund invests into ventures located in Saxony/Germany, Europe's leading semiconductor cluster. The team has invested into more than 120 companies so far, including more than 40 investments from the currentfund.

Investment focus

Software, Information Technology, Health Care
Seed, Series A, Funding Round
Germany, United States

Portfolio highlights

Zepta — Zepta emphasizes "digital solutions and sustainability in pest control." Zepta develops a digital approach for protecting humans from pests.
Prodlane — B2B Product Management SaaS solution
LipoCheck — LipoCheck is a healthtech startup that focuses on improving the diagnosis and treatment of lipedema, a condition that affects millions of women. The company offers a digital platform that serves as a support system for patients and treating physicians. LipoCheck's services include helping patients recognize lipedema and providing assistance inbecoming symptom-free. The platform was developed with the experiences of practicing doctors, product managers, and software developers. In addition to its digital services, LipoCheck also offers a range of merchandise including hoodies and shirts.

BioMedPartners is one of the leading European venture capital firms providing private equity and mezzanine financing to early- and mid-stage healthcare and human life science companies. They target the entire industry with special focus on pharmaceuticals, biotechnology, diagnostics and medical technology.

Investment focus

Biotechnology, Health Care, Medical
Series A, Series B, Series C
Switzerland, Germany, France

Portfolio highlights

ImmunOs Therapeutics — ImmunOs Therapeutics AG is a clinical-stage biotechnology company focused on discovering and developing next generation and novel human immunomodulatory proteins with a role in both innate and adaptive immunity.Their mission is to develop the next generation of novel therapeutics that will improve the lives of patients with serious disease.
TOLREMO therapeutics — TOLREMO therapeutics is striving to prevent the development of cancer therapy resistance through its proprietary drug discovery and development platform. Learn more about us.
Tubulis — Reimagining Antibody Drug Conjugates Tubulis generates uniquely matched protein-drug conjugates through the combination of novel proprietary technologies and disease-specific biologic insight. Our goal is to expand the therapeutic potential of antibody-drug conjugates (ADCs) by increasing design flexibility while overcoming constraints of toxicity, efficacy and indication. Tubulis will build new conjugates to fill its pipeline and

Techno Venture Management is a venture capital and private equity firm focused on healthcare industry.

Investment focus

Biotechnology, Health Care, Pharmaceutical
Funding Round, Series B, Series A
United States, Germany, United Kingdom

Portfolio highlights

Streaming21 — Checkout the full domain details of Streaming21.com. Click Buy Now to instantly start the transaction or Make an offer to the seller!
Helomics — Helomics® is a comprehensive personalized healthcare company, bringing the next generation of diagnostics to the oncology field. Helomics is dedicated to improving patient outcomes by providing a personalized comprehensive tumor profile utilizing a proprietary set of laboratory platforms that leverage both tissue-based live and fixed cellular basedanalysis allowing physicians to characterize malignant tumors on a personalized basis. Helomics’ novel molecular and cellular markers and bioinformatics services support treatment decisions by providing vital information based on the specific biological processes of each individual’s cancer.
Precision Therapeutics — Precision Therapeutics is a pharmaceutical research and development business that develops personalized cancer treatments for patients.

Impacting the future of medicine.

Investment focus

Biotechnology, Health Care, Medical
Series B, Series A, Series C
United States, United Kingdom, The Netherlands

Portfolio highlights

Numab — Numab Therapeutics AG
Verdiva Bio — Verdiva Bio is committed to developing next-generation therapies to help people living with obesity, cardiometabolic disorders, and related complications achieve better outcomes via more patient-friendly therapeutic options.
Orbis Medicines — Orbis Medicines is a novel macrocyclic chemistry and computational platform for high-throughput drug discovery.

Coparion provides venture capital to accelerate momentum and growth. With a currently active fund of EUR 275 million, Coparion has the means to do so.Coparion supports entrepreneurial vision with know-how, but without intervening in daily business operations. Thanks to in-depth experience in venture capital and in building companies, the Coparionteam discerns potential and opens up new perspectives. Coparion has the substance, tenacity, and creativity required to mutually manage difficult situations successfully.Coparion only invests with co-investors. The fund invests up to EUR 15M per company, usually in several financing rounds of EUR 0.5-8M each. The investment focus is on German companies in the start-up and early growth phases. Coparion is based in Cologne and Berlin.

Investment focus

Software, SaaS, FinTech
Series A, Seed, Series B
Germany, Switzerland, United States

Portfolio highlights

Finoa — Finoa is the leading European crypto-asset management platform, empowering businesses and institutions to engage with crypto safely and intuitively.
Protembis — ProtEmbo is designed to be a simple and reliable solution for one of the most feared complications during TAVR.The advent of transcatheter treatments for valvular heart disease has been a major revolution in the care of patients with disabilities or intercurrent illnesses that precluded undergoing stressful open cardiac surgical procedures.Nonetheless, in spite of ongoing improvements in TAVR procedures and outcomes, the occurrence of cerebrovascular events represents a significant morbidity of TAVR.Protembis was founded based on the vision to reduce the risk of cerebrovascular events, thereby improving outcomes and making TAVR even safer – especially in light of TAVR shifting to younger and lower-risk patients. The ProtEmbo System is an adjunctive device used during TAVR and removed following completion of valve implantation. The ProtEmbo is an intra-aortic filter device that is designed to deflect embolic material arising during TAVR away from the cerebral circulation.
Tubulis — Reimagining Antibody Drug Conjugates Tubulis generates uniquely matched protein-drug conjugates through the combination of novel proprietary technologies and disease-specific biologic insight. Our goal is to expand the therapeutic potential of antibody-drug conjugates (ADCs) by increasing design flexibility while overcoming constraints of toxicity, efficacy and indication. Tubulis will build new conjugates to fill its pipeline and

eCAPITAL is a venture capital investor that provides early to growth stage funding to technology and deep tech companies.

Investment focus

Information Technology, Software, Manufacturing
Series A, Funding Round, Series B
Germany, United States, Italy

Portfolio highlights

Exein — Exein provides the most advanced IoT security solution to protect your devices and containers. Protect your IoT devices in real time and at scale.
BeeOLED — BeeOLED’s technology enables OLED displays with significantly improved efficiency, brightness and operational stability at lower overall costs due to a less complex device structure.
Dryad Networks — Overview of Dryad, providing ultra-early fire detection as well as forest growth and health monitoring.

We have been investing at the frontier of technology and science for over 30 years. We know what it takes to succeed.

Investment focus

Software, Health Care, Biotechnology
Series A, Funding Round, Series B
Germany, Switzerland, United States

Portfolio highlights

Ledgy — Digitize your cap table, automate equity plans and simplify compliance. Find out how leading companies use Ledgy to empower their employees and engage investors.
HeyJobs — Intelligent recruiting | more hires with performance marketing | only qualified candidates | fast recruiting success | over 1,500 companies use HeyJobs to find employees
Humanoo — HUMANOO | MAKING PEOPLE HEALTHIER! HUMANOO is the digital health platform for employees and insurance clients. We enable our users to improve their physical and mental health. Simple, effective, proven - all in one app. With customized programs and innovative eHealth solutions, we guide our users in the areas of fitness, physio, yoga, mindfulnessand nutrition to their self-imposed goals. For the first time, companies and insurance companies can use comprehensive decentralized analysis to understand the health of their employees or insurance clients and make it a measurable success. Our team currently consists of 65 employees from 15 nations with different talents. In our office in Berlin-Kreuzberg, software developers, designers, marketing and sales specialists work together with sports and nutrition scientists as well as yoga teachers and physiotherapists. What we share is the goal to motivate people to stay healthy.

bmp Ventures is an innovative Venture Capital Company from Berlin. Since 1997 we’ve been investing Smart Money in Early Stage and Growth Startups. We finance ingenious business models with outstanding teams, who build fast-growing and sustainably profitable enterprises.

Investment focus

Information Technology, Software, Manufacturing
Seed, Funding Round, Series A
Germany, United States, Austria

Portfolio highlights

Livil — Livil provides a toolkit for designing and delivering flexible employee benefits, including lifestyle, dental, and vision plans.
RAYDIAX — We are Raydiax.Interventional only.Our goal is to reinvent computer tomography that is focussed on treatment.
XenoPatch GmbH — First-ever portable device for pain management, seamlessly combines heat, cold and vibration treatment with an intuitive smartphone app.

IBB Ventures is for all those who make a difference and create a sustainable future. We invest public funds as venture capital and, together with Berlin startups, help to promote our capital as a business location.

Investment focus

Software, Health Care, Internet
Seed, Funding Round, Series A
Germany, United States, United Kingdom

Portfolio highlights

Mediaire — mediaire supports radiologists with AI-based tools for MRI reporting. This enables them to make a more accurate and objective assessment even faster.
ARC Intelligence — ARC Intelligence operates as a supplier of data systems driven by AI for small and medium-sized businesses.
dsb Deutsche Sanierungsberatung — dsb Deutsche Sanierungsberatung provides easy and sustainable solutions for climate-friendly homes energy-efficient renovations for homeowners.

Innovative post-revenue startups with first customers trust us as highly reliable investors. We have been an active player in the venture capital market for over 25 years. Due to our evergreen approach, we offer institutional venture capital without the limitations of the usual fund structure. Predominantly we invest straight equity. Additionally,we can offer venture debt to mature startups close to break-even in order to avoid further dilution for founders. Being a private investment company we act as both lead investor or co-investor. We can also fulfill the private lead investor role for public investors like Bayern Kapital. Together we are increasing YOUR company's value.

Investment focus

Software, Information Technology, Health Care
Funding Round, Series A, Series B
Germany, Italy, United States

Portfolio highlights

DcubeD — Accelerate your space exploration through durable and affordable Release Actuators, Solar Arrays, and Deployables from DCUBED.
Parkstory — Parkstory offers fully automated parking solutions that are supported by artificial intelligence.
StoryBox — StoryBox provides a Software as a Service solution for businesses to create, share and structure video content to make it searchable. With the system, companies can create and organize smartphone-based videos for any application scenario. Using the app, videos can be created and shared by every employee using templates. The app suggests picturesettings and scene lengths automatically and offers an automated creation which includes corporate design. The content can be stored in the DSGVO-compliant StoryBox cloud and can be accessed, filtered and analyzed from anywhere. Customers include Iveco, Erste Group, Evonik, Alten, and KTM.

EMBL Ventures invest throughout Europe with the aim to build companies that create significant commercial opportunities based on new therapeutic treatment.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Series C
Germany, Austria, Ireland

Portfolio highlights

Arsanis — Arsanis is a clinical-stage biopharmaceutical company focused on applying monoclonal antibody (mAb) immunotherapies to address serious infectious diseases. A deep understanding of the pathogenesis of infection, paired with access to some of the most advanced mAb discovery techniques and platforms available today, has positioned Arsanis to build andadvance a pipeline of novel mAbs with multiple mechanisms of action and high potency against their intended targets.The company’s lead clinical program, ASN100, is aimed at serious Staphylococcus aureus infections and is being evaluated in Phase 2 clinical trial for the prevention of S. aureus pneumonia in high-risk, mechanically ventilated patients. In addition to ASN100, its preclinical pipeline is comprised of mAbs targeting multiple serious bacterial and viral pathogens, including respiratory syncytial virus.Arsanis is a U.S. company headquartered in Waltham, Massachusetts, with European research and preclinical development operations headquartered in Vienna, Austria (Arsanis Biosciences GmbH).
Topas Therapeutics — Topas Therapeutics GmbH is a private Hamburg, Germany-based biotechnology company focused on developing products to address areas of major unmet need, including autoimmune diseases, allergies and anti-drug antibodies. The Topas Particle Conjugates technology platform induces antigen-specific immune tolerance by harnessing the liver’s naturalimmunology capabilities. The Company has several proprietary programs; lead product candidate TPM203 has recently entered clinical testing for pemphigus vulgaris, an orphan disease. Other programs are in anti-drug antibodies, celiac disease, Type 1 diabetes, as well as a multiple sclerosis program that is available for partnering.Topas has a research and option agreement with Eli Lilly and Company focused on antigen-specific tolerance induction and a multi-year agreement with Boehringer Ingelheim to collaborate in the field of anti-drug antibodies.Topas’ investors include: Epidarex Capital, Gimv, EMBL Ventures, Evotec and Boehringer Ingelheim Venture Fund.
Crescendo Biologics — Crescendo Biologics is a new Cambridge-based company whose vision is to deliver next-generation antibody therapeutics based on novel class-leading platforms.The focus of the company is on developing platforms that will address key issues in generating high-affinity, soluble, human VH antibody fragments. These are the smallest fragments thatretain antibody binding, and have many desirable properties as potential therapeutics. Crescendo will then utilise these platforms for product development of in-house targets or in partnership with other companies.

bm|t supports innovative and growth-oriented companies in Thuringia with equity investments and venture capital.

Investment focus

Software, Information Technology, Health Care
Seed, Funding Round, Series A
Germany, United States

Portfolio highlights

rooom — rooom is a global startup based in Germany, launched in 2019. The company’s experienceCloud is an all-in-one platform for creating, managing and promoting engaging 2D, 3D, AR & VR experiences. It works across all desktop and mobile devices. rooom’s experienceCloud is designed to cover the marketing and visualization needs of differentindustries through their comprehensive product portfolio. These include eventCloud (optimized for virtual events, exhibitions, conferences, meetings), spaceCloud (real estate, property, museums), productCloud (3D products, product showrooms) and immerseCloud (tours, guides, 3D books). rooom’s eventCloud is routinely hosting up to 200,000 users for hybrid events like IFA, Berlin and for global customers such as Porsche, Deutsche Telekom, DHL and E.ON. rooom has won over 20 awards, including the Global Eventex Award (twice), the Innovation & Excellence Award and the German Innovation Award.
Zepta — Zepta emphasizes "digital solutions and sustainability in pest control." Zepta develops a digital approach for protecting humans from pests.
Enginsight — Enginsight GmbH was founded in August 2017. With a highly motivated team, they are working together on the vision of providing companies with a solution that will enable them to safely and confidently navigate the digital future. Enginsight helps leading companies autonomously monitor and secure their entire IT landscape. Certified and highlytrained employees form the heart of Enginsight, together with partner companies around the globe. They analyze and monitor complete IT landscapes – recognize the connections and dependencies between websites and servers up to IoT-devices. The innovative software platform acts autonomously and points out the critical paths, risks and threats.

Providing capital plus strategic, clinical, operational, financial, and commercial support to deliver the added value inventors seek.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Series C
United States, Germany, United Kingdom

Portfolio highlights

Evommune — Evommune is taking a tissue-based approach to advance insights and accelerate the development of transformative medicines in inflammatory diseases.
Muna Therapeutics — Muna Therapeutics discovers and develops therapies that slow or stop neurodegenerative diseases such as alzheimer’s and parkinson's.
HotSpot Therapeutics — HotSpot Therapeutics is a biotech startup that focuses on the development of allosteric therapies targeting regulatory sites on proteins. It develops a therapy platform to discover medicines and provide proper treatment to identify hotspots and locate pathway treatments for cancer, metabolic and rare diseases, leverages a database of hotspotstructures, harnessing the power of data science in its multidisciplinary approach to drug discovery, and helps patients to get treatment against several diseases.HotSpot Therapeutics was founded in 2017 and is headquartered in Boston, Massachusetts.

Seed Fonds has a strong competence network with national and international investors, business angels & expertes from the industry. They are specialized in the development of comprehensive financing models offering stability and development opportunities on the long term.

Investment focus

Biotechnology, Medical, Health Care
Funding Round, Seed, Series A
Germany

Portfolio highlights

miacosa — miacosa.de is operated by the Endorsed Goods GmbH. miacosa.de is a social shopping concept from Germany based in Cologne. Social Shopping the miacosa way means that members select their personal shopping team of experts and celebrities that present products they love on miacosa.de Miacosa is for members only. The free service starts with productsfrom the fields of Health Style, Home & Living, Kitchen and fashion accessories.
Hemovent — Based in Aachen, Germany, Hemovent is a privately held medical technology company that is developing a portable ECMO (Extra Corporeal Membrane Oxygenation) unit. Hemovent was founded by serial entrepreneur, Christof Lenz and Oliver Marseille, inventors of the company’s proprietary platform. It is the goal of the company to develop aninnovative solution, with precision and craftsmanship, that will aide patients with lung and heart function while allowing them to be mobile.
aquila biolabs — aquila biolabs is a German technology company focusing on the development of innovative laboratory devices for the analysis of shake-flask fermentations in biotechnological, chemical and pharmaceutical research and development.

Investing in the Future of Protein.We invest in visionary founders creating the future of food and materials.

Investment focus

Food and Beverage, Food Processing, Biotechnology
Series A, Seed, Series B
United States, Israel, United Kingdom

Portfolio highlights

ENOUGH — ENOUGH makes protein sustainable by producing ABUNDA mycoprotein, made by fermenting fungi with the natural sugars from grains. It is a whole protein with all 9 essential amino acids & rich in fibre. It is a B2B ingredient, neutral in taste and fibrous in texture, like meat. The most sustainable
Shiru — Discover Shiru. We are an Ingredient Company that Identifies and Creates Functional Ingredients for the Plant-Based Industry.
Wanda Fish Technologies — Wanda Fish is an innovative FoodTech company with a platform that produces a wide variety of delicious fish fillets using sustainable cell-cultivation practices.

EQT Ventures is a European VC fund with just over €2.3 billion in total capital raised. EQT Ventures I launched in May 2016, with commitments totaling €566 million and a simple mission - to be the kind of VC the team would have liked to have had on their own startup journeys. Recognizing that building and growing a company takes more than justcapital, the EQT Ventures team provides founders with support and advice throughout different stages of growth. EQT Ventures doesn't focus on particular markets or industries, but on bold and ambitious founders who have the grit and determination to build global success stories. EQT Ventures II launched in November 2019, with commitments totaling €660 million. EQT Ventures III launched in 2022, with commitments totaling €1.1 billion, making it the biggest European Venture Capital fund committed to early-stage tech startups. The EQT Ventures team is based across six offices in London, Stockholm, Berlin, Paris, Amsterdam, Paris, and San Francisco, taking a locals-with-locals approach and supporting founders on the ground. Motherbrain, EQT Ventures' in-house-developed artificial intelligence (AI) platform, ensures the team has a data-driven approach and has driven more than $100 million in portfolio company investments.

Investment focus

Software, Artificial Intelligence, Information Technology
Series A, Seed, Series B
Germany, Sweden, United States

Portfolio highlights

MarvelX — Transform Your Operations With Trusted AI Agents. MarvelX AI Agents take care of repetitive, high-stakes workflows so your team can focus on the exceptions, not the routine. Built for insurance and beyond.
Paid — Paid is a business platform for AI agents.
Marvel Fusion — Our mission is to enable humankind to access clean, safe & reliable energy by building a laser-driven fusion power plant.

Andera Partners, formerly known as Edmond de Rothschild Investment Partners (EdRIP) As heir to the traditions and values that have ensured the success of the Rothschild family for 250 years, the Edmond de Rothschild Group has established itself over time as a leading player in European finance. Its activities are grouped around two major areas:Private Banking and Asset Management. The Group offers wealthy families, entrepreneurs, and large institutions a full range of solutions combining a culture of tailored solutions, stability, performance, and innovation. The Edmond de Rothschild Group’s offering is characterised by strong convictions, with the desire to guarantee to each of its customers: A unique, close relationship, underpinned by the know-how and the variety of expertise of a large international group; Autonomous, experienced teams, who anticipate economic trends and innovate to establish long-term performance; The recognised stability, strength, and independence of a family-owned financial group. Founded by Baron Edmond de Rothschild in 1953, the Group has been chaired by his son, Baron Benjamin de Rothschild, since 1997.

Investment focus

Biotechnology, Health Care, Medical
Series B, Private Equity, Funding Round
France, United States, Germany

Portfolio highlights

FIRE1 — FIRE1 and is based in Dublin, Ireland, will focus on developing novel therapeutic devices.
Evommune — Evommune is taking a tissue-based approach to advance insights and accelerate the development of transformative medicines in inflammatory diseases.
Bioptimus — Our mission is to build the first universal AI foundation model for biology to fuel breakthrough discoveries and accelerate innovations in biomedicine and beyond.

With a track record of over 20 years in venture capital and experience from more than 200 investments in numerous companies BFB Brandenburg Kapital GmbH (BFB) is the most active equity investor in Brandenburg. BFB invests in fast-growing technology-orientated companies throughout the whole life-cycle. Target sectors are ICT/Digital Economy,Life Science, MedTech, Proptech, Industrial Applications. BFB invests in companies based in or with facilities in Brandenburg. The current VC fund is financed by the European Regional Development Fund (ERDF) an Investitionsbank des Landes Brandenburg (ILB).

Investment focus

Information Technology, Software, Health Care
Seed, Series A, Funding Round
Germany, United Kingdom

Portfolio highlights

family.cards — Family.cards provides elders with barrier-free access to digital solutions and all the tools they need to manage their circumstances.
Green Fusion — Green Fusion is developing a cloud-based energy manager for the intelligent control of heat, electricity, and e-mobility. The focus here is on hybrid heating systems in buildings such as heat pumps + gas boilers and the coupling to photovoltaic systems and electric vehicle charging stations.
Sphingotec GmbH — Improving patient outcomes with innovative diagnostics for critical care: Actionable insights in real-time

BlueYard backs founders building the interconnected elements that can become the fabric of our future.

Investment focus

Software, Biotechnology, Internet
Seed, Series A, Funding Round
United States, Germany, United Kingdom

Portfolio highlights

Cryptio — We offer enterprise-grade accounting, reporting, and audit software for your digital assets.
Castelion — We are a modern defense production company building the next generation of military hypersonic, vehicle, and strike systems to deter future wars.
Grouphug — Generates memes from the archive of group WhatsApp chats

Amino Collective is an institutional venture capital firm investing at seed stage in health and bio companies. They help bring life-changing ideas to life by backing, connecting, and advancing our collective of entrepreneurs and scientists. The firm intends to invest in the sectors of biology, biotech, health tech, science, digital health, lifescience, and synthetic biology.

Investment focus

Health Care, Biotechnology, Medical
Seed, Pre-Seed, Series A
United States, Germany, United Kingdom

Portfolio highlights

Rivia — Integrated Clinical Trial Intelligence. Drive therapeutic evaluation and trial management with real-time insights.
Inductive Bio — Bringing the data, ML, software, and expertise needed to rapidly solve your most challenging ADMET problems.
Tandem Health — Focus on providing care, while Tandem helps you easily write medical notes directly after the patient consultation.

S-Venture Capital Dortmund aims to fund technology companies and is a German regional investment group.

Investment focus

Biotechnology, Guides, Genetics
Series B, Funding Round, Series A
Germany

Portfolio highlights

Innolume — Innolume has invented a novel comb laser light engine for short-reach optical interconnects between and within computers. Economical wavelength-division multiplexing (WDM) is enabled by this class of low-cost, low-power Fabry-Perot lasers. WDM, familiar from telecom, provides an efficient alternative to multiple lasers and underutilized parallelfiber/waveguides, reducing short-reach system cost and power.
Protagen — Protagen is a precision medicine specialist that support drug development, facilitate treatment strategies and improve patient management. Protagen is at the forefront of immuno-profiling and the discovery of novel autoantibody signatures for autoimmune disease and immuno-oncology. Protagen’s SeroTag® technology identifies biomarkers that address anumber of challenges currently hindering the successful development and broader application of both cancer immunotherapies and novel treatments for autoimmune diseases.The company is a leader in patient stratification for autoimmune disease, having developed disease-specific NavigAID stratification panels that profile individual patient’s autoimmune condition and immune status. This precision medicine approach allows for the development and implementation of more targeted therapies for diseases such as systemic lupus erythematosus (SLE), systemic sclerosis (SSc), rheumatoid arthritis (RA), Sjögren’s syndrome (SjS) and others.
Scienion — SCIENION AG is a life science company well positioned in the markets of ultra-low volume liquid handling systems and microarray technologies. They provide their customers with an integrated product portfolio facilitating and improving multiparallel bioanalytics, high throughput screening and high throughput production of microarrays in the genomicsand proteomics fields â€“ from early research to manufacturing.

Grazia Equity is a venture Capital firm investing in innovative, technology driven startups with high potential.Based in Stuttgart (Germany), Grazia has been supporting a large number of mostly young companies, often from their foundation to the Initial Public Offering or eventual sale. In contrast to other venture capital firms, theypredominantly work with their own capital that they invest as entrepreneurs.

Investment focus

Internet, E-Commerce, Biotechnology
Series A, Series B, Seed
Germany, United States, Switzerland

Portfolio highlights

Vytal — Start the Packaging Revolution! We are offering smart & reusable To-Go Packaging-as-a-Service to gastronomy clients & consumers.In Germany the consumption of take-away, convenience and delivery food & drinks is responsible for about 281 kilotons of single-use packaging waste for immediate consumption and is growing at double digitrates. Most of the time, To-Go food containers, snack boxes or coffee cups have a very short life-span of only 30 minutes after which they are tossed into trash (or litter parks, beaches & the ocean). This is not only a giant waste of economic resources as each single use costs between 15 and up to 0,60€ for a stable bowl/box with a lid. It is a horrendous waste of environmental resources (wood, water, crude oil, metals & energy) that are used to produce this packaging. Therefore, a single use packaging not weighing more than 30 grams can easily come with an ecological backpack of more than 8 kilograms when taking into account all the resources used in production (material intensities taken from Wuppertal Institute for Climate, Environment and Energy). Looking at GHG emissions, the picture is similarly bleak: Using CO2 emission factors and the detailed material mix of the single-use packaging waste analyzed by NABU (German Nature and Biodiversity Conservation Union), the 281 thousand tons waste from To-Go consumption generated around 556 thousand tons of CO2 or the equivalent of 195k passenger cars per year (assuming an average distance travelled of 15,000km). With the expected rise of take-away, convenience and delivery food, the related emissions are expected to increase at double digit rates as waste volume is expected to increase and as we saw a shift to plastics relative to cardboard or other materials. While there is a growing awareness of the problem, especially in Germany, there is no scalable solution yet and the commonly used alternative of nature-based & ‘biodegradable’ materials like bagasse or PLA also require many resources for production & transport, and have to be incinerated or go to landfill after use as there is currently no way to compost them.
Lumotive — Lumotive is a Seattle-based startup company developing high performance, solid-state lidar for autonomous systems in the automotive, UAV, robotics and related industries. The company's revolutionary beam-steering technology leverages Liquid Crystal Metasurfaces (or LCMs) implemented in mature semiconductor manufacturing processes to deliversmall, inexpensive 3D perception systems with unprecedented performance and reliability. For more information, visit us at www.lumotive.com.
Affinity — Join over 60,000 who trust the Affinity mobile app to manage your personal banking needs and qualify for an Affinity Instant Loan

The German Federal Ministry of Education and Research funds research programs and institutions, supervises nuclear energy, and establishes educational policy in general.

Investment focus

Biotechnology, Medical, Health Care
Grant, Seed, Series B
Germany, United States, Denmark

Portfolio highlights

NetBird — Wiretrustee is an open-source VPN platform built on top of WireGuard® making it easy to create secure private networks for your organization or home. It requires zero configuration effort leaving behind the hassle of opening ports, complex firewall rules, VPN gateways, and so forth.
CyberTide — CyberTide is an AI-based Data Leak Prevention Solution
NVision Imaging Technologies — NVision Imaging Technologies is leveraging advances in quantum physics to enable the first routine, convenient and affordable use of Magnetic Resonance Imaging (MRI) for assessing early patient response to cancer treatment at the metabolic level.

start-ups, SMEs, technology, co-investment

Investment focus

Biotechnology, Health Care, Information Technology
Pre-Seed, Seed, Funding Round
Germany, The Netherlands, Austria

Portfolio highlights

Filuta AI — Operationalized Composite Artificial Intelligence
Resistell AG — Resistell is a antibiotic resistance test.
iThera Medical — Explore optoacoustic imaging technology for non-invasive in vivo visualization and quantification of disease-related tissue biomarkers.

SFO is an entrepreneur from the start-up environment and medium-sized companies. SFO offers complementary expertise, reliable capital, and an effective network.

Investment focus

Food and Beverage, B2C, Pet
Seed, Pre-Seed, Series A
Germany

Portfolio highlights

Younikat — VEGDOG - vegan dog food is the first 100% vegetable and gluten-free complete feed for dogs, which was developed in a one-year development phase in cooperation with specialist veterinarians and specialist laboratories due to a feed allergy in our dog Nelson.
ecoLocked — ecoLocked is your partner to create a climate-positive built environment. We develop CO2-optimized recipes for concrete based on carbon-negative biochar admixes. Our admixes allow to store captured CO2 in buildings, reduce direct emissions from concrete production, and provide multiple functional benefits, such as improved thermal insulation.
ProteinDistillery — ProteinDistillery: The Future of Sustainable Protein Production. We transform industrial side-streams into functional protein ingredients.

Investing early in Europe's most passionate founders.

Investment focus

Health Care, Financial Services, Software
Seed, Series A, Funding Round
Germany, Austria, United Kingdom

Portfolio highlights

LiveEO — LiveEO is the leading solution provider for AI-powered satellite-based monitoring of large infrastructure networks. Trusted worldwide.
OneTwenty — OneTwenty is an early-stage health tech start-up that develops multiple Machine Learning based solutions for people with diabetes as well as Medtech companies for sensor optimization, biomarker prediction, glucoregulatory models, and iAGC (interoperable automated glycemic controller). Our solution demonstrates unprecedented precision in bloodglucose prediction 120 minutes in advance. OneTwenty revolutionizes the life of people with Type 1 diabetes.
HealthCaters — HealthCaters is a connected care solution for companies that allows them to empower their employees to take control of their health.

UVC Partners is a Munich- and Berlin-based early-stage venture capital firm that invests in technology-based startups in the areas of enterprise software, industrial technologies, and mobility. The fund typically invests between € 0.5 - 10m initially and up to € 20m in total per company.

Investment focus

Software, Information Technology, SaaS
Seed, Series A, Series B
Germany, Switzerland, Denmark

Portfolio highlights

Predium — Predium is the software platform for real estate owners to measure, manage and communicate their ESG performance.
DeepDrive — We are DeepDrive. We are powered by fusion. Absolute professionalism mixed up with our deeply rooted urge to discover. Deep expertise meets revolutionary innovations.
Enginsight — Enginsight GmbH was founded in August 2017. With a highly motivated team, they are working together on the vision of providing companies with a solution that will enable them to safely and confidently navigate the digital future. Enginsight helps leading companies autonomously monitor and secure their entire IT landscape. Certified and highlytrained employees form the heart of Enginsight, together with partner companies around the globe. They analyze and monitor complete IT landscapes – recognize the connections and dependencies between websites and servers up to IoT-devices. The innovative software platform acts autonomously and points out the critical paths, risks and threats.

Gilde Healthcare is a specialized European healthcare investor managing two business lines: a lower mid-market buy-out fund and a venture & growth capital fund. It has over €800 million ($900 million) under management and is actively looking to lead new investments in digital health, diagnostics, medical devices, therapeutics and healthcareservices. Gilde successfully builds healthcare businesses across Europe and US, investing up to €35 million in a single portfolio company.

Investment focus

Biotechnology, Health Care, Medical
Series B, Series C, Series A
United States, The Netherlands, Germany

Portfolio highlights

FIRE1 — FIRE1 and is based in Dublin, Ireland, will focus on developing novel therapeutic devices.
Noema Pharma — BEYOND SYMPTOM CONTROL Developing therapies to help both orphan and larger patient populations with conditions of the brain and nervous system live their li ...
Alleviant Medical — Interventional therapy for congestive heart failure

Good Seed Ventures is a Venture Capital firm that exclusively invests in sustainable food tech.

Investment focus

Food and Beverage, Food Processing, Biotechnology
Seed, Series A, Pre-Seed
Germany, Israel, United States

Portfolio highlights

Lovely Day Foods — We harness the power of plants and cutting-edge technology to crack the egg.
Libre Foods — MEAT, BUT MAKE IT MUSHROOMS. GET READY TO TASTE THE POWER OF FUNGI
Nosh Biofoods — We create nutritional and highly functional proteins from non-GMO fungi. Our proprietary ferementation process is minimal, scalable, and sustainable.

Possible Ventures backs ambitious teams building frontier technology to positively impact society. We invest globally in the early stages, actively supporting founders via our collective of global entrepreneurs.

Investment focus

Software, Information Technology, Biotechnology
Seed, Pre-Seed, Series A
Germany, Australia, United States

Portfolio highlights

Heidi Health — Heidi Health is modernizing primary care with AI-powered technologies to improve care's quality and accessibility. its creators and engineers is to completely eradicate missed and sluggish diagnoses worldwide. They are committed to bridging the gap between the level of care that patients desire and the level of care that doctors can delivergiven their budget constraints. To create a platform where patients can quickly and easily get the treatment they require and to give every clinician the resources they need to deliver care that is secure, efficient,
HyperHeat — HyperHeat is a climate tech startup, that develops a breakthrough solution for zero-carbon industrial heat at very high temperatures.
Hippos Exoskeleton — Hippos Exoskeleton created an auto-inflating knee brace to avoid tears in the ACL and other injuries.

Venture capital investment can raise funds for your small business. Venture Capital Firms in the UK like Agronomics is a biotech venture capital firm which invest into the clean meat sector.

Investment focus

Biotechnology, Food and Beverage, Food Processing
Seed, Series A, Series B
United States, Finland, Germany

Portfolio highlights

GALY — Saving Our Planet by Transitioning the World to Cellular Agriculture
Onego Bio — Onego Bio is a cell ag company, specialized in animal-free egg white protein. We produce bioalbumen with an innovative precision fermentation process.
Liberation Labs — Liberation Labs believe that by innovating technology, It can free the world from the costs of industrialized agriculture and unlock a new era of accessible, healthy foods. The mission is to make precision fermentation by commercializing purpose-built manufacturing facilities for industrial biotech.

Seventure Partners is a French venture capital firm targeting in Tech/Digital and Life Sciences companies. It funds innovation and participates in the entrepreneurial adventure, alongside entrepreneurs and sharing their passion.Founded in 1997, Seventure Partners is one of the European leaders in venture capital, with € 1 billion undermanagement as of December 31, 2023. It is an active partner of innovative companies that, according to the management team, show strong growth potential and evolving in two fields of activity: Digital Technologies and Life Sciences. With more than 20 employees, including some 15 investors, Seventure Partners has a proven track record and in-depth expertise in technology, entrepreneurship, and various private equity operations.Seventure's goal is to identify and support the development of tomorrow's European leaders in order to accelerate their growth. To do this, the firm provides entrepreneurs with the expertise, networks, and know-how of its internal team of investors.The different funds/verticals on which Seventure Partners are focusing on today: - Life Sciences : Biotech, Healthcare, Nutrition - Tech/Digital : B2B SaaS, Fintech, Retailtech, Cybersecurity - Sports & Wellbeing - Blue Economy

Investment focus

Biotechnology, Health Care, Software
Series A, Funding Round, Series B
France, United States, Germany

Portfolio highlights

Ekstere — Ekstere facilitates selling and purchasing verified-quality used bicycles at a reasonable price.
Anybuddy — Anybuddy is a sport booking marketplace, leader in racket sport in France
Seaweed Concept — Seaweed Concept is a marine biotechnology company, that focuses on the innovative utilization of seaweed to provide high-quality ingredients to various industrial sectors

Global Asset Fund is a private equity firm based in Germany that finances early and later stage venture investments. The fund enables the development of products and technologies that address a growing market of tomorrow.

Investment focus

Medical, Therapeutics, Biotechnology
Series A, Series B, Funding Round
Germany

Portfolio highlights

Siltectra — SILTECTRA is a high-tech company specializing in kerfless wafering and thinning, an innovative new technology for manufacturing wafers. Kerfless wafering by SILTECTRA is a platform technology which can be used in a wide variety of industries and for many different materials.
Isarna Therapeutics — Isarna Therapeutics has an unmatched commitment to developing selective TGF-β inhibitors to effectively treat ophthalmic diseases. They are advancing a unique pipeline of novel oligonucleotides and combination modalities to transcend clinical response and improve patient outcomes.

Lowercarbon Capital backs kickass companies slashing CO2 emissions, sucking carbon out of the sky, and buying us time to unf**k the planet.

Investment focus

Renewable Energy, Biotechnology, Energy
Series A, Seed, Series B
United States, United Kingdom, France

Portfolio highlights

Gridware — Using remote telemetry and edge AI, Gridware wildfire prevention technology powers a grid that is smarter and more reliable than ever before.
Biosphere — Biosphere engages in manufacturing commercial-scale fermentation products and robotic greenhouses.
Pendulum Systems (formerly Macro-Eyes) — Pendulum Systems is an AI company building the first intelligent supply chain planning platform.Pendulum AI predicts demand, optimizes supply, and puts assets on the map, all while continuously improving on its own. Our technology is the result of a decade of rigorous research and development and has been deployed across some of the mostdemanding environments on Earth.Today, Pendulum is at work for corporations and governments across six continents, driving margins and saving lives.In 2023, Macro-Eyes became Pendulum, shifting from an R&D focus to productization and commercial growth.

Delivery Hero Ventures is backed by Delivery Hero, a truly global food delivery platform - whose network, distribution and expertise can be harnessed to help our portfolio companies fulfill their global ambitions.

Investment focus

E-Commerce, Information Technology, Food Delivery
Series A, Seed, Series B
Singapore, Egypt, Brazil

Portfolio highlights

Charan — Charan is an operator of an e-commerce platform intended to sell second-hand fashion apparel.
Qashier — One Qashier solution streamlines POS & payment operations empowering businesses to thrive in the digital economy. Be More with Qashier.
OneOrder — One Order delivers exceptional produce, custom cuts of meat, high-quality seafood, and imported foods offering an array of global flavors.

At better ventures we invest in early-stage founders who aim to change our world for the better.

Investment focus

Software, Environmental Consulting, E-Commerce
Pre-Seed, Seed, Series A
Germany, Switzerland

Portfolio highlights

TRAIT — TRAIT Running Coach app for your iphone or ipad tablet.
Lichtwart — Lichtwart is a startup that creates a cloud control platform for efficiently controlling and maintaining lighting systems.
PL BioScience — Animal-free cell culture supplements derived from human platelets. Supporting cell expansion and maintenance from research to therapy.

We are the home for entrepreneurs with a big vision who want to create something less ordinary. Something that matters. For all of us.

Investment focus

Health Care, Software, Information Technology
Seed, Funding Round, Series A
Germany, United Kingdom, Finland

Portfolio highlights

Elio — Putting leading scientific data into context, to enable others to respond to climate change’s dynamism and act on solutions with confidence.
Ocean Ledger — Precision analytics to design, implement & monitor coastal mitigation and adaptation.
NatureMetrics — NatureMetrics is the World-Leading provider of Biodiversity monitoring data, using eDNA surveys, metabarcoding & more. Book your demo today!

Providing capital plus strategic, clinical, operational, financial, and commercial support to deliver the added value inventors seek.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Series C
United States, The Netherlands, Switzerland

Portfolio highlights

Perfuze — Perfuze was founded in 2018 by Wayne Allen and Liam Mullins. Perfuze is located within Galway City in the West of Ireland. The founders have over 30 years combined medtech experience within start-up and large corporations.Perfuze is developing innovative medical technology to treat acute ischemic stroke.Perfuze is developing innovative cathetertechnology to treat acute ischemic stroke. Their technology is intended to provide superior clinical outcomes in shorter procedural times; resulting in safe, cost-effective therapy. Perfuze was founded in 2018 by Wayne Allen and Liam Mullins. The founders have over 30 years combined medtech experience within start-up and large corporations. Perfuze is currently located in the Business Innovation Centre on the campus of the National University of Ireland, Galway, and is in the process of relocating to the IDA Business Park in Dangan, Galway.
Avidicure — Avidicure is developing dual agonistic avidity-engineered multifunctional antibodies, AVC-Boosters, as monotherapy for treatment of cancer
Atalanta Therapeutics — Atalanta was created to address the urgent global need for interventions to treat neurodegenerative diseases.

VF-Funds for innovative and scalable start-ups from the Rhineland Area, Germany

Investment focus

Software, Health Care, Manufacturing
Seed, Series A, Pre-Seed
Germany, Spain

Portfolio highlights

IonKraft — IonKraft can provide better performance at a lower cost while maintaining recyclability, they also promote material reduction and reuse and are commercializing the technology with funding from the German Federal Ministry for Economic Affairs and Energy (BMWi).
PL BioScience — Animal-free cell culture supplements derived from human platelets. Supporting cell expansion and maintenance from research to therapy.
Black Semiconductor — Black Semiconductor manufacture microchips with integrated electronic-photonic circuits using graphene technology.

TVM Capital Life Science is one of the transatlantic Venture Capital pioneers with teams based in North America and Europe.

Investment focus

Biotechnology, Health Care, Pharmaceutical
Series B, Funding Round, Series C
United States, Germany, United Kingdom

Portfolio highlights

Definiens — Definiens is the provider of image analysis and data mining solutions for quantitative digital pathology in the life sciences, diagnostic biomarkers and healthcare industries. Definiens software provides detailed readouts from whole tissue slides, cell-based assays and full body scans and allows correlating this information with data derived fromother sources. By automating analysis workflows, Definiens helps pharmaceutical and biotechnology companies, research institutions, clinical service organizations and pathologists to generate new knowledge and supports better decisions in research, diagnostics and therapy. Definiens’ vision is to open new fields of research, to contribute to development of personalized medicine and to significantly improve the quality of patients’ lives. Definiens is headquartered in Munich, Germany, and has offices throughout the United States.
Lamab Biologics — Lamab Biologics operates as a biotechnology company. Lamab Biologics develop first-in-class monoclonal antibody prophylactic therapeutic targeting IgE, a key mediator for allergic diseases.
Rapid Micro Biosystems — Rapid Micro Biosystems provides products for the detection of microbial contamination in the manufacture of pharmaceutical, biotechnology, and personal care products. It offers the Growth Direct System, a non-destructive method for microbial enumeration. The company was formerly known as Genomic Profiling Systems and changed its name to RapidMicro Biosystems in 2007. Rapid Micro Biosystems was founded in 2006 and is based in Bedford, Massachusetts.

96 Normal 0 false false false EN-GB X-NONE X-NONE

Investment focus

Medical, Health Care, Biotechnology
Series A, Seed, Series B
Germany, Finland, The Netherlands

Portfolio highlights

Surgify — Surgify are currently preparing the commercialization of a novel technology for bone surgery at Aalto University with financial support from Tekes (Finnish Funding Agency for Innovation). To enable continuous communication with clinicians, they have been working in close cooperation with Neurosurgical Department of Helsinki University CentralHospital, part of HUS (The Hospital District of Helsinki and Uusimaa).
ATRO Medical — ATRO Medical is a spin-out from DSM and Radboudumc and builds on the knowledge developed in the Public-Private Collaboration BioMedical Materials that started in 2010 with a consortium of universities, private companies, and financial support from the Dutch government. The collaboration between the clinical, biomechanical, and polymer expertise hascreated the base for the Trammpolin design and the development towards a prototype.
microDimensions — microDimensions provides digital pathology software and services: image analysis, 3D histology reconstruction, protein multiplexing, stereology, image registration.